Navigation Links
Nutrastar Announces Adoption of Share Repurchase Program
Date:8/25/2011

HARBIN, China, Aug. 25, 2011 /PRNewswire-Asia-FirstCall/ -- Nutrastar International Inc. (OTCBB: NUIN; "Nutrastar" or the "Company"), a leading producer and supplier of premium branded Traditional Chinese Medicine ("TCM") consumer products, today announced that its Board of Directors has authorized a share repurchase program under which Nutrastar may repurchase up to US$5 million of the Company's common stock over a period of 12 months.

Under the program, the Company may, from time to time make one or more purchases, through open market, block trades or in privately negotiated transactions in accordance with the applicable federal securities laws and regulations, including Rule 10b-18. The timing and extent of the repurchases will be determined by the Company's management, in its discretion, and will depend upon market conditions, the trading prices and volume of the stock, alternative uses for capital, the Company's financial performance, and other factors. The repurchase program does not obligate Nutrastar to make any repurchases at any specific time.  

Ms. Lianyun Han, CEO and founder of Nutrastar, commented, "Despite difficult macroeconomic conditions and volatility in the capital markets, we are confident in our business, our growth strategies and in the opportunities that lie ahead for our company. We stand by the legitimacy and validity of our cash position, financial results and internal controls that are reviewed and audited by our top-10 accounting firm. Our shareholders are vitally important to us and the adoption of this share repurchase program reflects our strong commitment to enhancing shareholder value as well as the confidence our Board of Directors and management team have in our ability to continue carrying out our growth strategy of expanding our product lines and distribution networks while also adding value to our shareholders in the long-term."

The program will be funded utilizing the Company's cash on hand and cash generated from operations. The Company is currently working with financial institutions to secure efficient and adequate conversion of Chinese Renminbi to U.S. Dollars to fund the execution of the repurchase program. The Board of Directors of the Company will periodically review the share repurchase program and may authorize adjustments to the program's terms and size. The Board of Directors may also suspend or discontinue the repurchase program at any time.  

About Nutrastar International Inc.Nutrastar is a China based leading producer and supplier of premium branded TCM consumer products including commercially cultivated Cordyceps Militaris and functional health beverages. Cordyceps Militaris is one of the most highly regarded herbal nutrients in TCM. The Company believes it is the largest manufacturer of bioengineered Cordyceps Militaris in China, ranked by volume, according to China Market Monitoring Center (CMMC), accounting for approximately 19% market share in China. The Company is headquartered in Harbin, capital of Heilongjiang province, with 321 employees, 21 in R&D, and 140 in sales and marketing. The products of Nutrastar are sold throughout China via a direct and distribution network that covers more than 10 provinces. More information may be found at http://www.nutrastarintl.com/ or e-mail: ir@nutrastarintl.com

Make sure you are first to receive timely up-to-date information on Nutrastar. Sign up for Nutrastar's email news alert system today at: http://www.nutrastarintl.com/alerts

Safe Harbor StatementThis news release contains "forward-looking statements" relating to the business of Nutrastar International Inc., its subsidiaries and other affiliate companies. All statements, other than statements of historical fact included herein are "forward-looking statements" including statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Other than as required under the securities laws, the Company does not assume a duty to update any forward-looking statements to reflect events or circumstances after the date hereof.For more information, please contact:Robert Tick, CFONutrastar International Inc.Email: roberttick@nutrastarintl.com Howard GostfrandAmerican Capital VenturesTel:  +1-305-918-7000Email: info@amcapventures.com
'/>"/>

SOURCE Nutrastar International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nutrastar to Present at the Cowen and Company 9th Annual Consumer Conference in NYC
2. Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011
3. Nutrastar Distribution Spreads into Anhui Province
4. Nutrastar Provides First Quarter 2011 Financial Results Release Date and Conference Call Details
5. Nutrastar to Participate in Brean Murray, Carret & Co.s 2011 Beijing China Growth Conference
6. Nutrastar to Present at the Upcoming 2011 Global Hunter Securities Conference
7. Nutrastar Announces Second Quarter 2011 Financial Results
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... SAN DIEGO and SEOUL, ... -- Silicon Biosys­tems Menarini and Macrogen, Inc. today ... clinical assays and innovative procedures for precision medicine ... to combine Silicon Biosystems, DEPArray™ digital-sorting technology with ... development of tests certified under the Clinical Laboratory ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
(Date:2/11/2016)... 2016 Stem cells are primitive cells found ... and the capacity to differentiate into mature cell types ... the first mouse embryonic stem cells were derived from ... that the first culturing of embryonic stem cells from ... produced until 2006 As a result of these discoveries, ...
Breaking Medicine Technology:
(Date:2/13/2016)... , ... February 13, 2016 , ... Many individuals looking ... protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved into ... once more, but without the high-carb repercussions. IsoPasta has 30 grams of protein ...
(Date:2/13/2016)... ... 2016 , ... When an Au Pair comes all the way around the world ... for and they are often worried things won’t go well. More often than not, however, ... Au Pair of the Year winner’s all commented how their Au Pairs have become a ...
(Date:2/12/2016)... LA (PRWEB) , ... February 12, 2016 , ... The ... St. Landry and Evangeline Parishes. The purpose of these scholarships is to encourage ... encourage those individuals to seek employment within these two parishes. , “We have ...
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical ... in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the ... products in action, learn more about their chosen field and network with their colleagues. ...
(Date:2/12/2016)... ... February 12, 2016 , ... Itopia, a leader in cloud ... Clarity Intelligence Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. ... their small and medium business (SMB) clients. , In recent years, ...
Breaking Medicine News(10 mins):